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INNOVATIVE METHODS FOR STAKEHOLDER ENGAGEMENT: AN
ENVIRONMENTAL SCAN
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Moon M1
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OBJECTIVES: Involving stakeholders in research helps ensure that research is rele-
vant and responsive to stakeholder needswhile improving the quality of the research.
This researchwas conducted as part of AHRQ’s Community Forumprojectwhichwas
chargedwith identifyingemergingstrategiesandstateof theartmethods for engaging
stakeholders. METHODS: We developed a conceptual framework for stakeholder
engagement that informed this literature scan and assisted in organizing findings.
The scan included a search of peer-reviewed literature, using academic databases
as well as an Internet search of grey literature and Web sites. Our final review
included 23 peer-reviewed articles, 15 grey literature documents, and 43Web sites
related to stakeholder engagement. To supplement our scan, we conducted 11
interviews with individuals experienced in the field of stakeholder engagement.
Our technical experts also suggested organizations andWeb sites to explore in our
literature review. RESULTS: We identified many promising methods of involving
stakeholders in research. One example is using online collaborative platforms to en-
able interactions between an organization and its stakeholders through a virtual
space. These allowusers to share information,work together, andprovide feedback to
stakeholders about how their input is being used. Other examples include product
development challenges, utilizing existing online communities, and grassroots com-
munity organizing. Selected recommended practices fromour review include gaining
trust of stakeholders before involvement and maintaining throughout; selecting
stakeholders for whom the decision or research has important consequences; and
educating stakeholders on their roles, their responsibilities, and the topics being dis-
cussed.A limitation toourfindings is that there are limited evaluationdatameasuring
outcomeeffectiveness of thesemethods.CONCLUSIONS: Stakeholder involvement is
critical to health care research. This presentation will highlight selected effective and
creative approaches to stakeholder engagement.
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PROFILE OF CARE FOR SEXUALLY TRANSMITTED INFECTIONS (STIS) IN
HEALTH CENTERS IN BORDER AREAS OF CENTRAL AMERICA
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OBJECTIVES: To analyze the profile of care for sexually transmitted infections
(STIs) in health centers in border areas of Central America. METHODS: A cross-
sectional study in a sample of 3357 people receivedmedical care for some STIs in 13
health centers in border areas of Central America, during 2007-2010. Doctors were
trained and suppliedmedicines, condoms and HIV testing (basic package of health
care). The sample of users was characterized according to sociodemographic vari-
ables and the associated factors with the probability of receiving the basic package
of care for STIs were analyzed using additive probit regression models. RESULTS:
Of the total users, 66% had 25 to 59 years old, and 93% of users were women. The
most frequently diagnosed STI were Candidiasis, Bacterial Vaginosis, Trichomo-
niasis, Gonorrhea and Syphilis. 60% of prescriptions for these STIs were adhered to
the international recommendations. 53.1 % of users received onlymedicines, 5.8 %
received medicines plus HIV testing, 30.8 % received medicines plus condoms and
only 10% of them received the complete basic package. The likelihood of receiving
was lower in women. CONCLUSIONS: It is not enough to increase service delivery
capacity to change care practices. These are deeply rooted in the sociocultural
context related notions and cultural biases. Highlights gendered medical practices
that adversely affect the profile of care.
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OBJECTIVES: Pompe disease is a rare disease that affects between 5,000 and 10,000
people worldwide. It is an inheritedmetabolic myopathy caused by deficiency of acid
alpha-glucosidase (GAA) enzyme in lysosomal cells. The purpose of this study was to
review and compare recent developments in Pompe disease therapy.METHODS: Us-
ing PubMed and other Internet-based search engines, we reviewed Pompe disease
epidemiology and recent new drug development, and compared two newly-ap-
proved therapies in terms of their indications, efficacy, and safety profiles.
RESULTS: The incidence of Pompe disease varies among different populations,
ranging from 0.0032% in African Americans to 0.002% for the Chinese. There are
two forms of Pompedisease: infantile-onset and late-onset. The survival rate to age
one is about 25.7% for those with the infantile-onset disease. Two new drugs are
both enzyme replacement therapies (ERTs), including Myozyme® (alglucosidase
alfa, rhGAA) and Lumizyme® (alglucosidase alfa). They were approved as orphan
drugs by the U.S. Food and Drug Administration in 2006 and 2010, respectively.
Both are biologics that have beenmarketed around the world. While Myozyme® is
indicated for infantile-onset, Lumizyme® is for children 8 years old or older. Both
drugs improve the survival rate, but there remains a need to monitor risk of heart
and lung failure among those on treatment. CONCLUSIONS: Although ERT is an
approved effective treatment for Pompe disease, gene therapy is under develop-
ment in order to correct sequence coding gene for the deficient enzyme into cells.
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OBJECTIVES: To explore the data sources used in economic evaluations performed
on new drugs, and to propose an improved data infrastructure in order to deal with
future value-based decision making in health care policy in Japan.METHODS:We
systematically reviewed economic evaluation studies of the new drugswhichwere
launched in Japan betweenApril 2006 andMarch 2011, andwhich have been priced
by the cost calculation method, one of two types of pricing for new drugs in Japan.
The “Ichushi” and Pubmed databases were used to find the published articles.
RESULTS: A total of 198 drugs were priced under cost calculation methods in the
last 5 years in Japan. Fourteen published articles (9 drugs) were found: 5 CUAs and
10 CEAs (including one that was both CUA and CEA). In all studies, several data
from different sources were incorporated. Cost data were estimated by using stan-
dard treatment protocols and national price lists for drugs andmedical services, or
obtained from a limited number of claims data. Efficacy data were obtained from
RCTs or clinical trial data mostly conducted in Japan. In 4 out of the 5 CUAs, utility
data were used from other studies conducted on non-Japanese samples, and 2
CUAs did not consider transferability issues. Other data, such as epidemiological
data, were adopted from overseas as well as Japanese studies; usually mortality
rates were from Japanese statistics, while incident rates were from overseas.
CONCLUSIONS: In order to increase quality and efficiency to conduct economic
evaluations on new drugs, three steps need to be taken in the data environment:
increased accessibility to large cost databases such as the national claims data-
base; establish an epidemiological database; and collect and accumulate utility
data in Japanese samples.
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OBJECTIVES: Despite much research to understand patient nonadherence, clear
research-based evidence of how to reduce non-adherence remains elusive. This
paper describes two related studies conducted as part of the FP7 European Com-
mission funded Ascertaining Barriers to Compliance (ABC) project. We sought to
develop consensus-based policy solutions to address medicines adherence and
benchmark current implementation activity for those policy solutions.METHODS:
Delphi study: A 4-round Delphi study was conducted with 49 participants from 14
countries, representative of a range of stakeholder groups. Participants engaged in
the study remotely, anonymously and electronically. Participants responded to
open questions about the causes, consequences and solutions to medication non
adherence. Subsequent rounds refined responses, and sought ratings of the rela-
tive importance, operational and political feasibility of each potential solution to
medication nonadherence. Feedback of responses was provided to participants
after each round. A consensus meeting was held to discuss and further refine the
proposed policy solutions. National self-assessment study: An online survey and
follow-up telephone interview were conducted based on policy solutions resulting
from the consensus study. National medicines leads within the Ministries of
Health for the 27 European Union member states were invited to participate. Par-
ticipants rated the extent and appropriateness of implementation of each policy
solution in their country. RESULTS AND CONCLUSIONS: Twenty-five policy solu-
tions were prioritised based on composite scores for importance, operational and
political feasibility. Prioritised policy solutions focused on interventions for pa-
tients, training for healthcare professionals, and actions to support patient-clini-
cian partnership. Few solutions concerned actions by governments, health care
payers, or interventions at the system level. Implementation varied across nations.
Some European nations had not identified medication adherence as a priority and
tended to be concernedwith developingmore general clinical governance arrange-
ments. Some European nations had more systematic, co-ordinated approaches to
implementing policy solutions to address medication nonadherence.
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OBJECTIVES: Medicines that are considered to be clinically effective but not cost-
effective by the Pharmaceutical Benefits Advisory Committee (PBAC) may be reim-
bursed in Australia through two pathways: by meeting the ‘rule of rescue’ (RoR)
criteria to be listed on the Pharmaceutical Benefits Scheme, or being included on
the life-saving drugs programme (LSDP). The criteria for the RoR and LSDP share
some similarities, but the LSDP criteria are less subjective andmore restrictive.We
sought to analyse and compare outcomes for submissions that were considered
under the RoR and LSDP from2008 to 2011.METHODS: Public SummaryDocuments
of PBAC recommendations for 2008-2011 were reviewed to identify submissions
that were considered for reimbursement citing the RoR or requested listing on the
LSDP. Outcomes of the applications were analysed and Payer interviews were un-
A14 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
